Besides, miR155 enhances CD8+ T cell anti-tumor efficacy and proliferative activity by inhibiting T cell terminal differentiation and functional exhaustion through downregulation of the Akt inhibitor Ship1 and promoting expression of the polycomb repressor complex 2 (PRC2)-associated factor Phf19, indirectly leading to increased PRC2 activity (35). The gene discussed is AKT1; the disease is neoplasm.